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Summary
The frequency of CD4+ Foxp3+ regulatory T (Treg) cells is often signifi-
cantly increased in the blood of tumour-bearing mice and people with
cancer. Moreover, Treg cell frequencies are often higher in tumours com-
pared with blood and lymphoid organs. We wished to determine whether
certain chemokines expressed within the tumour mass selectively recruit
Treg cells, thereby contributing to their enrichment within the tumour-
infiltrating lymphocyte pool. To achieve this goal, the chemokine profile
of carcinogen-induced fibrosarcomas was determined, and the chemokine
receptor expression profiles of both CD4+ Foxp3 and CD4+ Foxp3+ T
cells were compared. These analyses revealed that the tumours are charac-
terized by expression of inflammatory chemokines (CCL2, CCL5, CCL7,
CCL8, CCL12, CXCL9, CXCL10 and CX3CL1), reflected by an enrich-
ment of activated Foxp3 and Foxp3+ T cells expressing T helper type 1-
associated chemokine receptors. Notably, we found that CXCR3+ T cells
were significantly enriched in the tumours although curiously we found
no evidence that CXCR3 was required for their recruitment. Instead,
CXCR3 marks a population of activated Foxp3 and Foxp3+ T cells,
which use multiple and overlapping ligand receptor pairs to guide their
migration to tumours. Collectively, these data indicate that enrichment of
Foxp3+ cells in tumours characterized by expression of inflammatory
chemokines, does not occur via a distinct chemokine axis, thus selective
chemokine blockade is unlikely to represent a meaningful therapeutic
strategy for preventing Treg cell accumulation in tumours.
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Introduction
Tumours are known to employ a number of mechanisms
to evade host immune responses. One such mechanism is
suppression of otherwise potent T cells,1 natural killer
cells,2 natural killer T cells3 and dendritic cells4 by
CD4+ Foxp3+ regulatory T (Treg) cells. It has been shown
in human tumours and in experimental animal models of
cancer that the frequency of Treg cells is significantly
increased in peripheral blood, lymph nodes and spleens
and that even higher frequencies are found within
tumours.5–7
Several mechanisms that may account for enrichment
of Treg cells are reviewed in ref. 8. There is evidence to
support a role for transforming growth factor-b in pro-
moting their proliferation in tumours and in tumour-
draining lymph nodes (TDLN)9,10 and also for driving
conversion of conventional CD4+ Foxp3 T cells (Tconv
cells) into CD4+ Foxp3+ Treg cells.11 In a previous study
whereby the carcinogen methylcholanthrene (MCA) was
used to induce fibrosarcomas in mice, we examined the
T-cell receptor (TCR) repertoires of Tconv cells and Treg
cells and found that the repertoires of tumour-infiltrating
Tconv and Treg cells were distinct. This lack of TCR
overlap observed between the two populations argues
strongly against the hypothesis that Treg cell enrichment
in tumours occurs through conversion of Tconv cells into
Treg cells.12 Another possibility is that intra-tumoural
Abbreviations: Ct, threshold cycle; NDLN, tumour non-draining lymph nodes; TDLN, lymph nodes draining the tumour
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Treg cell enrichment occurs through selective recruitment
of Treg cells via tumour-expressed chemokines.13–16 There
is however a general lack of comparative data on the
chemokine receptor expression profiles of Tconv versus
Treg cells, limiting the understanding of whether a single
or multiple chemokine(s) can selectively promote Treg
cell recruitment.
In the study described herein, we conducted a broad
analysis of chemokine expression by MCA-induced fibro-
sarcomas and a side-by-side analysis of Foxp3+ and
Foxp3 CD4+ T cells in terms of their phenotype and
migratory capacity. The study describes delineation of the
chemokine profile of MCA-induced tumours as well as
the chemokine receptors expressed by both Tconv and
Treg cells. This information was subsequently used to test
the hypothesis that the tumour chemokine profile allows
for selective accumulation of Treg cells, thereby contrib-
uting to immunosuppression within the tumour microen-
vironment.
Materials and methods
Mice
Six- to eight-week-old female C57BL/6 (Thy1.1) mice and
Foxp3-GFP transgenic mice, obtained from Professor
Alexander Rudensky,17 were housed under specific patho-
gen-free conditions. All experiments were conducted in
compliance with UK Home Office regulations.
Tumour induction
Mice were anaesthetized and injected subcutaneously (in
the hind leg) with 400 lg of 3-methylcholanthrene
(MCA; Sigma-Aldrich, St Louis, MO) in 100 ll of olive
oil. Tumours occurred between 80 and 150 days after
injection. Tumour-bearing mice were killed before the
tumours reached 15 cm in diameter.
RNA extraction and quantitative RT-PCR
Spleen, lymph node and tumour tissues were snap frozen
in liquid nitrogen and stored at 80° until needed. Total
RNA was extracted using TRIzol reagent (Invitrogen,
Carlsbad, CA) under the manufacturer’s specification.
The quantity and quality of RNA were determined using
the Agilent 2100 bioanalyzer (Agilent Technologies, Santa
Clara, CA), and only high-quality samples with an RNA
integrity number ≥ 8 were used for quantitative RT-PCR.
Five micrograms of total RNA (equivalent to 50 ng RNA
per gene) was used for first-strand cDNA synthesis and
elimination of contaminating genomic DNA, performed
using the RT2 First strand kit (SABiosciences, Frederick,
MD) as specified by the manufacturer. The cDNA was
used in a highly validated quantitative RT-PCR array
(RT2 ProfilerTM PCR array for Mouse inflammatory cyto-
kines and receptors; PAMM-011; SABiosciences) to detect
and quantify gene expression levels. Samples were run in
a 96-well plate in an ABI 7900HT FAST Block instrument
(Applied Biosystems, Foster City, CA) using a two-step
cycling programme as follows: step 1, 95° for 10 min;
step 2, 95° for 15 seconds, followed by 60° for 1 min;
step 2 was repeated for 40 cycles. Data were analysed
using the DDCt method. Specific mRNA expression levels
for each gene were normalized as a ratio relative to
expression of internal control housekeeping genes, namely
glucuronidase b (Gusb), hypoxanthine guanine phospho-
ribosyl transferase 1 (Hprt1), heat-shock protein 90 000 a
cytosolic class B member 1 (Hsp90ab1), glyceraldehyde-3-
phosphate dehydrogenase (Gapdh) and cytoplasmic
b-actin (Actb).
Lymphocyte isolation
Spleens and lymph nodes were disrupted by mashing
through a 40-lm nylon cell strainer (BD Biosciences, San
Jose, CA) using a sterile 2-ml syringe plunger. Tumours
were excised and chopped into pieces using scalpel blades.
The pieces were then mashed with a syringe plunger and
the resulting cell suspension was filtered through 70-lm
nylon cell strainers (BD Biosciences). The cell suspensions
were then centrifuged before red blood cells lysis using
ammonium–chloride–potassium lysis buffer (Gibco,
Grand Island, NY).
Flow cytometry and antibodies
Mononuclear cells isolated from spleens, lymph nodes
and tumours were first stained with a dead cell marker
(LIVE/DEAD Fixable Aqua stain; Invitrogen) according
to the manufacturer’s instructions. Cells were then
washed and stained for cell surface markers and chemoki-
ne receptors. Stained cells were washed, fixed and
acquired on a FACS Canto II flow cytometer (BD Bio-
sciences). Data analysis was performed using SUMMIT 4.3
software (Dako, Glostrup, Denmark). The antibodies used
were as follows: anti-CD4-Pacific Blue antibody (BioLeg-
end, San Diego, CA), goat polyclonal antibody to CCR1
(Santa Cruz Biotechnology, Santa Cruz, CA) followed
with phycoerythrin (PE)-conjugated rabbit polyclonal
antibody to goat IgG (Abcam, Cambridge, UK), rabbit
monoclonal antibody to CCR2 (Abcam) followed with
PE-conjugated donkey polyclonal antibody to rabbit IgG
(Abcam), anti-CCR4-PE-Cy7 (BioLegend),anti-CCR3-
Alexa Fluor 647 (BioLegend), biotin-conjugated anti-
CCR5 antibodies followed with streptavidin-PerCP-Cy5.5
(both from eBioscience, San Diego, CA), anti-CXCR3-
APC (eBioscience, San Diego, CA), anti-CXCR4-APC
(BD Biosciences), rabbit polyclonal antibody to anti-
CX3CR1 (Abcam) followed with PE-conjugated donkey
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polyclonal antibody to rabbit IgG (Abcam). Foxp3
expression was detected by GFP fluorescence.
Chemokine receptor desensitization
For CXCR3 desensitization, splenocytes were treated with
500 nM of CXCL10 for 20 min. To inhibit signalling via
chemokine receptors, splenocytes were treated with 25 nM
Pertussis toxin for 20 min.
In vivo migration assays
CD4+ T cells were isolated from spleens of donor mice by
negative isolation with a CD4+ T-cell mouse isolation kit
II (Miltenyi Biotec, Bergisch Gladbach, Germany) as
detailed in the manufacturer’s protocol. The purified
CD4+ T cells were adoptively transferred by intravenous
injection and homing observed approximately 24 hr later.
Adoptively transferred cells were identified by labelling
with fluorescent dyes PKH26 or CFSE and in some
instances donor cells were distinguished based on Thy1.2
versus Thy1.1 expression. At the end of the transfer per-
iod spleens, lymph nodes and tumours were harvested
and the recovered cells were enumerated by flow cytome-
try. The ratio of Treg cells to Tconv cells in the input
fraction of donor cells was compared with that of recov-
ered migrated cells. Antibodies used were: anti-CD90.1
(Thy1.1)- PerCP-Cy5.5 (clone OX-7; BioLegend) and
anti-CD90.2 (Thy1.2)-PE (clone 30-H12; BioLegend).
Spleen cells purified from naive wild-type (WT) or
CXCR3/ mice were labelled with the fluorescent dye
PKH26 (Sigma, St Louis, MO) or Claret (Sigma) and
2 9 106 cells were injected (100 ll) intravenously. Single
cell suspensions were prepared from the spleens, inguinal
lymph nodes and tumours approximately 18 hr later and
stained with antibodies against CD4. Stained cells were
analysed by flow cytometry as described above.
Results
MCA-induced fibrosarcomas do not preferentially
attract Foxp3+ T cells
We first wished to determine whether Foxp3+ T cells were
more likely to migrate to carcinogen-induced fibrosarco-
mas compared with Foxp3 T cells. To achieve this, sple-
nic T cells were purified and labelled before intravenous
injection into tumour-bearing mice. After approximately
24 hr T cells were recovered for analysis by flow cytome-
try (Fig. 1). Although we observed a trend for preferential
migration of Treg cells to the tumour and a significant
enrichment in the spleen compared with the lymph nodes
(Fig. 1a) we found that Foxp3+ T cells recovered from
the tumour were not enriched within the recovered CD4+
T-cell population compared with the input population
(Fig. 1b), thereby indicating that Foxp3+ T cells are not
more likely than Foxp3 T cells to migrate to the tumour
mass.
Chemokine signature of MCA-induced fibrosarcomas
We next wished to address whether the chemokines
attracting Foxp3+ and Foxp3 T cells to the fibrosarco-
mas were the same or distinct in nature. For this purpose,
we first identified the candidate chemokines that could
facilitate recruitment of CD4+ T cells into the tumour
mass. A quantitative RT-PCR array was used to analyse
the expression of 26 chemokine genes in tissue samples
obtained from tumours, spleens and lymph nodes of
tumour-bearing mice. To ensure detection of low copy
number chemokine genes we used a relatively high
amount of total RNA (50 ng/ml) for each gene analysed.
Some of the common housekeeping genes are de-regu-
lated in several cancers,18 so the extent of variation in the
level of expression of five housekeeping genes (Gusb,
Hprt1, Hsp90ab1, Gapdh and Actb) in tumour tissues
(compared with spleens and TDLN) was examined to
assess their potential as internal controls for normalizing
specific chemokine mRNA expression. Indeed as shown
in the Supporting information (Fig. S1a), there were sig-
nificant variations (P < 00001) in the expression of these
genes, with Hsp90 being expressed at highest levels. While
Gusb and Hprt1 were expressed at consistent levels,
Gapdh and Actb showed the least consistency between
tumours. We also compared the level of expression in
tumour, spleen and TDLN samples derived from the
same animal but found no significant variation between
P < 0·05
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Figure 1. Methylcholanthrene-induced fibrosarcomas do not prefer-
entially attract Foxp3+ T cells. In three independent experiments,
CD4+ T cells isolated from spleens were labelled with CFSE, adop-
tively transferred into tumour-bearing recipients and 24 hr later,
cells from the spleen, non-draining lymph nodes (NDLN), tumour-
draining lymph nodes (TDLN) and tumour were analysed by flow
cytometry. (a) Frequencies of CD4+ Foxp3+ T cells among the adop-
tively transferred cells recovered from spleens, NDLN, TDLN and
tumours. Horizontal lines represent the medians. One-way analysis
of variance/Dunn’s post-hoc test were used for statistical analysis. (b)
Percentage of CD4+ T cells expressing Foxp3 among the input T-cell
population and following their recovery from tumours, approxi-
mately 24 hr later.
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tumours and spleen or TDLN (see Supporting informa-
tion, Fig. S1b). Since Hprt1 expression showed the least
variation among tumours and among tumours, spleen
and TDLN, this gene was selected for data normalization.
As shown in Fig. 2(a), MCA-induced tumours showed
expression of the inflammatory chemokines CCL2
(MCP-1), CCL5 (RANTES), CCL7 (MCP-3), CCL8
(MCP-2), CCL12 (MCP-5), CXCL9 (MIG), CXCL10 (IP-
10), CXCL12 (SDF-1) and CX3CL1 (fractalkine). Each of
these chemokines was consistently expressed in all of the
MCA-induced tumours tested (Fig. 2b) and expression
of most, namely CCL2, CCL7, CCL8, CCL12 and
CX3CL1, was detectable only in the tumours and not in
spleen and lymphoid tissue. We conclude therefore that
these inflammatory chemokines represent the unique
chemokine signature of MCA-induced fibrosarcomas.
Although expression of CCL5, CXCL9, CXCL10 and
CXCL12 were also consistently detected in the tumours,
expression of each was also detected in spleen and
lymph node.
Chemokine receptor expression by tumour-infiltrating
CD4+ T Cells
Treg cells have been shown to express inflammatory
chemokine receptors and adhesion molecules suggestive of
an enhanced capacity to migrate to inflamed tissues.19–23
Whether this accounts for the enrichment of Treg cells
observed in tumours is not clear as, to our knowledge, few
studies have performed a side-by-side analysis of chemoki-
ne receptor expression by both tumour-infiltrating Foxp3+
and Foxp3 CD4+ T cells. Therefore, having estab-
lished the chemokine profile of the fibrosarcomas under
study, we next sought to quantify the proportions of
Tumour
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Figure 2. Quantitative RT-PCR for chemokine
gene expression. Total RNA was extracted from
tumours, spleens and lymph nodes and used
for quantitative RT-PCR analysis of various
chemokine genes as described in the Materials
and methods section. (a) Chemokine gene
expression profile of samples from tumour,
spleen and tumour-draining lymph nodes
(TDLN) of a tumour-bearing mouse. (b) Com-
parison of chemokine expression levels in
tumours from four mice. Gene expression was
normalized to Hprt1 expression as an internal
control within each tissue.
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tumour-infiltrating CD4+ T cells (both Foxp3+ and
Foxp3) that expressed the corresponding chemokine
receptors for these chemokines. Single cell suspensions
prepared from spleens, tumours, non-draining lymph
nodes (NDLN) and TDLN were analysed by flow cytome-
try to determine the expression of chemokine receptors by
Foxp3+ and Foxp3 T cells. The expression of chemokine
receptors binding the tumour signature chemokines
defined above was compared on Foxp3+ and
Foxp3 CD4+ T cells (Fig. 3). Expression of the inflam-
matory chemokine receptors, CCR1, CCR2, CCR3, CCR5
and CX3CR1, was significantly enriched on both Foxp3
+
and Foxp3 CD4+ T cells within the tumours when com-
pared with spleens and lymph nodes (Fig. 3b). These data
strongly indicate that inflammatory chemokines CCL2,
CCL7, CCL8, CCL12 and CX3CL1, all contribute to the
intra-tumoural recruitment of CD4+ T cells. In addition
the data demonstrate that significantly higher proportions
of Foxp3 compared with Foxp3+ T cells expressed CCR1
(P = 004), CCR2 (P = 003) and CX3CR1 (P = 003)
whereas no significant differences were observed in expres-
sion of CCR3 (P = 06) or CCR5 (P = 09) between the
two T-cell types. These data suggest that interactions
between the chemokine receptors CCR1, CCR2 and
CX3CR1 with their cognate ligands may favour recruit-
ment of Foxp3 (rather than Foxp3+) T cells to the
tumours. On the other hand, receptor–ligand interactions
for CCR3 and CCR5 would have no bias for either Foxp3+
or Foxp3 T cells. Although there is evidence that CCL22
found in ovarian cancers, serves to attract CCR4+ Treg
cells, we found no evidence for expression of its major
ligands CCL22 or CCL17 in the fibrosarcomas described
herein.13 However, some reports indicate that CCR4 may
bind other inflammatory chemokines such as CCL5 and
CCL2,24 so expression of the receptor was analysed on
both tumour-infiltrating Foxp3 and Foxp3+ T cells.
Although we observed a highly significant difference in
proportions of Foxp3 and Foxp3+ T cells expressing
CCR4 in spleens and lymph nodes, this difference was
considerably reduced in the tumour where CCR4 was
expressed on a high proportion of both Foxp3 and
Foxp3+ T cells (Fig. 3).
In contrast to these classical inflammatory chemokine
receptors, expression of CXCR3, which binds the inflam-
matory chemokines CXCL9 and CXCL10, was expressed
on T cells in all of the compartments analysed (Fig. 3b).
This is consistent with the detection of CXCL9 and
CXCL10 mRNA in spleens, lymph nodes and tumours.
There was also a further highly significant enrichment of
CXCR3+ T cells in the tumour compared with NDLN
and TDLN. These data support the hypothesis that
CXCR3+ T cells (Treg and Tconv) are preferentially
recruited to MCA-induced tumours.
To investigate the enrichment of CXCR3+ cells in
tumour, splenic CD4+ T cells were purified, PKH26-
labelled and adoptively transferred into tumour-bearing
mice. After 24 hr, tumour-infiltrating PKH26+ cells were
recovered and stained for CXCR3. When the frequencies
of CD4+ CXCR3+ T cells were compared among the
input and migrated fractions recovered from the tumour,
a significant enrichment of CXCR3+ CD4+ T cells was
found P = 0009 (Fig. 4a,b). This may reflect an enrich-
ment of activated T cells, marked by expression of
CXCR325,26 and/or preferential migration of CXCR3+ T
cells to the tumour. Moreover, a significantly higher fre-
quency of CD4+ T cells expressing CXCR3 was found in
the tumours compared with NDLN (Fig. 4c).
CXCR3 is not required for intra-tumoural
recruitment of CD4+ T cells
Based on the observation that CXCR3+ T cells are signifi-
cantly enriched in MCA-induced tumours, we postulated
that the CXCR3-binding chemokines (such as CXCL10)
were likely candidates for recruitment of T cells to the fi-
brosarcomas. Indeed immunohistochemical analyses con-
firmed the presence of CXCL10 within the tumour mass
(Fig. 5a). To determine whether CXCR3 was required for
intra-tumoural recruitment of CD4+ T cells we tested
whether CXCR3-desensitization through pre-incubation
with CXCL10 would interfere with the ability of adop-
tively transferred T cells to access the tumour. Despite
down-regulation of CXCR3 for several hours post-desen-
sitization, no difference in migration to the tumours was
observed when compared with the untreated cells
(Fig. 5b–d), suggesting that although CXCR3+ T cells are
enriched within tumour immigrants, CXCR3-expression
is not required for migration to occur.
To confirm that CXCR3 expression does not promote
T-cell migration to the MCA-induced tumours, we per-
formed adoptive transfer experiments where spleen cells
purified from WT and CXCR3/ mice were labelled
with the fluorescent dyes, PKH26 and Cellvue Claret,
respectively. The labelled cell populations were mixed and
injected intravenously into a tumour-bearing mouse.
After 18 hr, T cells were recovered from the spleen,
tumour and draining (inguinal) and non-draining
(contralateral inguinal) lymph nodes (Fig. 5e). At this
time-point, we found a trend for a small increase in the
proportion of WT cells in the spleen and both draining
and non-draining lymph nodes relative to the input popu-
lation. In contrast, most labelled CD4+ T cells recovered
from the tumour were from CXCR3/ animals. In a sec-
ond experiment, where the input ratio of WT : CXCR3/
CD4+ T cells was 12 : 1, we again saw a trend for an
increase in the proportion of WT cells in the spleen,
draining and non-draining lymph nodes relative to the
input population (13 : 1, 2 : 1 and 2 : 1, respectively)
but a small increase in CXCR3/ CD4+ T cells in the
tumour (09 : 1). Overall, the results obtained in the
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adoptive transfer experiments confirm that the absence of
CXCR3 does not impair CD4+ T-cell migration to MCA-
induced tumours, and implies that the significant enrich-
ment of CXCR3+ CD4+ T cells in tumours reflects their
activation status and not preferential migration through
the CXCR3 receptor.
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Figure 3. Analysis of chemokine receptor
expression by flow cytometry. Single cell sus-
pensions prepared from tumours, spleens and
lymph nodes were stained for various chemo-
kine receptors and analysed by flow cytometry.
(a) Representative FACS plots showing expres-
sion of CXCR3 on conventional T (Tconv)
and regulatory T (Treg) cells. (b) Frequency of
CD4+ T cells expressing chemokine receptors
in control (non-tumour-bearing) and tumour
bearing mice. Shaded and clear bars represent
Tconv and Treg cells, respectively. Letters S, L,
N, D and T denote spleen, lymph node, non-
draining lymph nodes (NDLN), tumour-drain-
ing lymph nodes (TDLN) and tumour, respec-
tively. Paired t-test was used for statistical
analysis. P-value interpretation: ***P ≤ 00009;
**P = 0001 to P = 0009; *P = 001 to P = –
005. The main chemokines that bind the
respective receptors are indicated in brackets.
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Multiple chemokines contribute to intra-tumoural
recruitment of T cells
It is likely that activated T cells express multiple chemoki-
ne receptors that facilitate guided migration and specific
positioning of the T cells within inflamed tissues includ-
ing tumours. To test the role of multiple chemokine
receptors in T-cell recruitment to tumours in vivo, CD4+
T cells purified from the spleens of tumour-free mice
were treated with Pertussis toxin, an inhibitor of signal-
ling by many chemokine receptors, before adoptive trans-
fer of the cells. An analysis of cells recovered after 24 hr
indicated that the Pertussis toxin treatment led to a dra-
matic reduction in migration of adoptively transferred
cells to the tumour and spleens (Fig. 6a,b), indicating a
major role for chemokine receptors in migration to these
sites. As expected, migration to the lymph nodes was
completely blocked by Pertussis toxin treatment.
As the data shown in Fig. 3 suggest co-expression of
CXCR3 and other inflammatory receptors, we looked for
co-expression of CXCR3 and other chemokine receptors
that are abundantly expressed by tumour-infiltrating Tconv
and Treg cells (i.e. CCR5 and CCR2). Data from a group of
at least four mice indicated that a high proportion of both
Foxp3+ and Foxp3 T cells, expressed CXCR3 with CCR2
and/or CCR5 (Fig. 6c,d). These data provide evidence for
significant overlaps in chemokine receptor expression and
indicate that enrichment of CXCR3+ T cells most likely
occurs through interactions with chemokines binding to
co-expressed chemokine receptors. Fundamentally, intra-
tumoural recruitment is not a ‘one-chemokine–one-recep-
tor task’ but rather a complex interaction of multiple
receptors and chemokines within a tumour-bearing mouse,
and as such recruitment-blockade cannot be achieved by
targeting a particular chemokine nor can a particular
chemokine axis be identified that would serve to block
Foxp3+ but not Foxp3 CD4+ T cells.
Discussion
In this study we set out to identify mechanisms under-
pinning the observation that Treg cells are enriched in
tumours. Such an observation has been made using
numerous mouse models and through the study of
patients with cancer. The aim of our work was to investi-
gate within the context of a carcinogen-induced tumour,
the relative contribution of chemokine-mediated recruit-
ment to the Treg-enrichment process and to determine
whether Foxp3+ and Foxp3 CD4+ T cells use the same
or different chemokines for migration to tumours, in this
case MCA-induced fibrosarcomas.
Analysis of the MCA-induced fibrosarcomas revealed a
tumour-specific inflammatory chemokine signature and
correspondingly, intra-tumoural enrichment of T cells
expressing the reciprocal chemokine receptors. This
enrichment, in the case of both Foxp3 and
Foxp3+ CD4+ T cells, was highly significant compared
with the spleen and lymph nodes, pointing to a continu-
ous chemokine-mediated recruitment of these T cells to
the tumours, a conclusion supported by the observation
that migration of adoptively transferred T cells to
tumours was inhibited by administration of Pertussis
toxin. For the most part, we found either no significant
difference in the proportions of Foxp3 and
Foxp3+ CD4+ T cells expressing a particular chemokine
receptor (CCR3 and CCR5) or, in the case of some
chemokine receptors, we found a significant difference in
favour of Foxp3 CD4+ T cells (CCR1, CCR2 and
CX3CR1); findings that are compatible with our observa-
tion that following adoptive transfer there was no evi-
dence for preferential migration of Foxp3+ T cells to the
tumour mass.
In the case of CXCR3, although we found that a greater
proportion of Foxp3+ T cells, compared with Foxp3– T
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cells, expressed CXCR3 in tumours, CXCR3 was more
prevalent on both cell types when comparing tumours to
lymph nodes. CXCR3 is a T helper type-1-associated
chemokine receptor involved in directing T cells to sites
of type 1 inflammation, which is compatible with the
chemokine profile of the tumours described herein
(ie CCL2, CCL5, CCL7, CCL8, CCL12, CX3CR1 and
CXCL10).27,28 A similar finding has been reported previ-
ously for human ovarian carcinomas, where CXCR3+ T
cells represented the majority of Foxp3+ and Foxp3 T
cells within the tumour mass.29 The authors of the study
postulated that CXCR3+ T cells accumulate in response
to type 1 inflammation thereby serving to suppress effec-
tor T cells of a T helper type 1 orientation, i.e. those that
would otherwise be involved in effective anti-tumour
immunity.
In terms of the Foxp3+ tumour-infiltrating T-cell pop-
ulation, detailed phenotypic characterization revealed
that the majority of these displayed an activated effector
memory phenotype, i.e. up-regulating CD44, down-regu-
lating both CCR7 and CD62L and expressing CD103.30
Treg cells exhibiting this phenotype have been described
as ‘inflammation-seeking’, highly suppressive and
expressing high levels of mRNA for inflammatory
chemokine receptors CCR2, CCR5 and CXCR3,31 consis-
tent with our observations that CXCR3 is co-expressed
with these receptors. In the case of the Foxp3 CD4+
T-cell population, the tumour-infiltrating T-cell popula-
tion is far more heterogeneous. Although CXCR3+ cells
were enriched in this population compared with spleen
and particularly lymph nodes, this conventional T-cell
population comprises both activated and naive T cells.
As we have described previously, naive T cells may
access MCA-induced fibrosarcomas via unconventional
routes such as aberrantly formed blood vessels and
lymphatics.30
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Figure 5. CXCR3 is not required for intra-
tumoural recruitment of CD4+ T cells. (a)
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were stained by immunohistochemistry for
detection of CXCL10 expression. (b). Desensi-
tization of CXCR3 expression by CXCL10
treatment and CXCR3 expression assessed 0, 4
and 24 hr later. (c, d) Mice received 2 9 107
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treated with 500 nM CXCL10 and then labelled
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half was left untreated (control) and labelled
with CFSE. After 24 hr, spleens, non-draining
lymph nodes (NDLN), tumour-draining lymph
nodes (TDLN) and tumours were harvested,
stained and analysed by flow cytometry. (c)
Representative plots showing numbers of cells
recovered. (d) Absolute numbers of cells recov-
ered from each organ. Results are representa-
tive of two independent experiments. (e).
PKH26-labelled wild-type (WT) and Claret-
labelled CXCR3/ spleen cells were injected
intravenously into a tumour-bearing mouse.
Around 18 hr later, the spleen, TDLN, NDLN
and tumour were harvested and single cell sus-
pensions were stained with CD4-specific anti-
bodies. Lymphocytes were gated using a live/
dead marker and proportions of dye-labelled
CD4+ cells in each of the compartments are
shown.
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Curiously, although CXCR3+ T cells were enriched
compared with CXCR3 T cells in the fibrosarcomas, we
found no evidence for a requirement for CXCR3 in the
migration process. As mentioned above, we found that
CXCR3 is co-expressed with other major receptors
(CCR5 and CCR2), suggesting that enrichment of
CXCR3+ cells most likely also occurs via recruitment by
the inflammatory chemokines CCL2, CCL5, CCL7 and
CCL8. Hence, enrichment of T cells expressing certain
chemokine receptors at a given site may not in itself iden-
tify a chemokine axis through which a cell is recruited,
but rather reflects the combination of chemokine recep-
tors expressed by that cell.
Other studies in animal models and humans have
implied that there is specific recruitment of Treg cells to
tumours via certain chemokines. It was recently demon-
strated that production of CCL21 in tumours serves to
recruit CCR7+ Treg cells, thereby promoting tumour
growth.15 This is not the case for the MCA-induced fi-
brosarcomas described herein. Although CCL21 can
readily be detected within these tumours, few
CCR7+ Foxp3+ T cells are found within the tumours
compared with a relatively large proportion of
CCR7+ Foxp3 T cells.15 Although the implications of
these findings are yet to be elucidated, the data certainly
argue against CCL21-CCR7 blockade as a means of pre-
venting Treg cell enrichment at least in the carcinogen-
induced tumours under study here. Other chemokines
have been implicated as important for recruitment of
Treg cells in different tumour models/cancers.8 A role
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Figure 6. Intra-tumoural recruitment of CD4+
T cells is chemokine dependent. Mice received
4 9 107 splenic CD4+ T cells isolated from
spleens of tumour-free Thy1.1 mice, half of
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and then labelled with PKH26 (desensitized
fraction). The other half were left untreated
(control) and labelled with CFSE. After 24 hr,
spleen, non-draining lymph nodes (NDLN),
tumour-draining lymph nodes (TDLN) and
tumour were harvested, stained and analysed
by flow cytometry. (a) Plots showing numbers
of cells recovered from a representative mouse.
(b) Absolute numbers of adoptively transferred
cells that were recovered from each organ of a
representative mouse. This experiment was car-
ried out on two separate occasions with similar
results. (c, d) Single cell suspensions prepared
from tumours, spleens and lymph nodes were
stained for various chemokine receptors and
analysed by flow cytometry. Proportions of
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for CCL20-mediated recruitment of CCR6+ Treg cells
has been demonstrated in a mouse model of colorectal
cancer, CCL17 and CCL22 influence recruitment of
CCR4+ Treg cells in gastric cancer and ovarian carci-
noma, and CCL5 can direct recruitment of CCR5+ Treg
cells in a murine model of pancreatic cancer.13,14,16,32
Collectively these findings point to heterogeneity in
chemokine expression between different tumours, which
is likely to be influenced not only by the tumour cells
themselves but also by the nature of the immune infil-
trate (e.g. the phenotype of the tumour-infiltrating mac-
rophages). Moreover, the results of some studies indicate
that chemokine blockade may reduce both the infiltra-
tion of Treg cells and conventional anti-tumour T cells
and furthermore, reduce the anti-tumour efficacy of
these anti-tumour effector cells.8 The results observed in
this study support that conclusion as the Treg and
Tconv cells display very similar profiles of chemokine
receptors. Overall therefore, in the case of many tumours
it is unlikely that chemokine blockade will prove effec-
tive at promoting tumour immunity through consistent
and selective reduction in intra-tumoural Treg cell num-
bers.
How therefore could Treg cells be targeted for the pur-
pose of cancer immunotherapy? The results of clinical tri-
als using low-dose cyclophosphamide indicate that
modulation of Treg cell frequencies in this way can result
in enhanced endogenous anti-tumour responses and
responses induced by vaccination. Whether such an
approach will prove useful for controlling tumour pro-
gression is yet to be seen. Knowledge of how Treg cells
become enriched in tumours should prove useful. Studies
of carcinogen-induced tumours and mouse models of
glioblastoma support the notion that proliferation of nat-
urally occurring T cells accounts for the enrichment of
Treg cells within tumours.33,34 A better understanding of
factors underpinning this process of preferential prolifera-
tion may reveal new and more effective targets for
manipulating Treg cell numbers within tumours.
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